Group 1: Halozyme Therapeutics - Halozyme Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for oncology by targeting the tumor microenvironment [1] - The company has a Zacks Rank of 1 (Strong Buy) and its current year earnings estimate has increased by 10.5% over the last 60 days [1] - Halozyme's shares have gained 36.2% over the last three months, significantly outperforming the S&P 500's gain of 7.5%, and it possesses a Momentum Score of A [2] Group 2: T. Rowe Price - T. Rowe Price is a global investment management organization offering a wide range of mutual funds, sub-advisory services, and separate account management for various investors [3] - The company also holds a Zacks Rank of 1 and has seen a 9% increase in its current year earnings estimate over the last 60 days [3] - T. Rowe Price's shares have increased by 14.2% over the last three months, again outperforming the S&P 500's gain of 7.5%, and it has a Momentum Score of A [4] Group 3: Cars.com - Cars.com operates an online automotive platform that provides listings for new and used vehicles, along with expert and consumer reviews and research tools [4] - The company has a Zacks Rank of 1 and its current year earnings estimate has risen by 2.3% over the last 60 days [4] - Cars.com's shares have appreciated by 22.3% over the last three months, surpassing the S&P 500's gain of 7.5%, and it also has a Momentum Score of A [5]